We are a specialty pharmaceutical company, located in Louisville, Kentucky, whose mission is to develop, license and commercialize unique and significant pharmaceuticals that address unmet medical needs or overcome the limitations of existing products.

Our product line consists of AP-rated Dantrolene Sodium for Injection for the treatment of malignant hyperthermia. In addition, another non-narcotic drug product (Lofexidine) for the treatment of opiate withdrawal symptoms is well under development.

Dantrolene Sodium for Injection our first product and the first generic substitute for Dantrium^® IV*.

Revonto™ (dantrolene sodium for injection), the first patented scientific advancement for the treatment of malignant hyperthermia that dramatically reduces reconstitution time of dantrolene sodium for injection to 20 seconds or until solution is clear.  It retains the cost savings of the original product while offering a significant improvement in patient pharmacotherapy.

Lofexidine for the relief of opiate detoxification symptoms. When approved, it will be the first and only non-narcotic drug approved to relieve the debilitating withdrawal symptoms associated with opiate detoxification.  We are seeking a co-development partner for Lofexidine.

At US WorldMeds, we’re committed to using science to make lives better. Look to us for additional innovative products in the future.

Dantrolene Sodium for Injection is indicated, along with appropriate supportive measures, for the management of fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. It is also indicated preoperatively and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible. Malignant hyperthermia is life threatening and requires immediate medical attention and treatment.

Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. There have been reports of thrombophlebitis following administration of intravenous dantrolene. There have been rare reports of urticaria and erythema possibly associated with the administration of i.v. dantrolene sodium.

Please see complete prescribing information for Dantrolene Sodium for Injection.

For More information on Malignant Hyperthermia please visit The Malignant Hyperthermia Association of the United States (MHAUS).

*Dantrium^® IV is a registered trade name of JHP Pharmaceuticals.